

# European Respiratory Society Annual Congress 2013

Pu

**Abstract Group:** 5.1. Airway Pharmacology and Treatment

**Keyword 1:** COPD - management **Keyword 2:** Bronchodilators **Keyword 3:** No keyword

**Title:** Once-daily QVA149 improves symptom scores in patients with COPD

Prof. Tobias 3532 Welte [Welte.Tobias@mh-hannover.de](mailto:Welte.Tobias@mh-hannover.de) MD <sup>1</sup>, Prof. Ronald 3533 Dahl [ronadahl@rm.dk](mailto:ronadahl@rm.dk) MD <sup>2</sup>, I  
hungta.chen@novartis.com <sup>3</sup>, Dr. Nicola 3535 Gallagher [nicola.gallagher@novartis.com](mailto:nicola.gallagher@novartis.com) <sup>4</sup>, Dr. Peter 3536 D'And  
peter.dandrea@novartis.com <sup>3</sup>, Dr. Vijay 3537 Alagappan [vijay.alagappan@novartis.com](mailto:vijay.alagappan@novartis.com) MD <sup>3</sup> and Dr. Donald 3  
donald.banerji@novartis.com MD <sup>3</sup>. <sup>1</sup> Department of Respiratory Medicine, Hannover Medical School, Hannover  
of Respiratory Diseases, Aarhus University Hospital, Aarhus, Denmark ; <sup>3</sup> Primary Care, Novartis Pharmaceutical  
Hanover, NJ, United States and <sup>4</sup> Primary Care, Novartis Horsham Research Centre, Horsham, United Kingdom

**Body:** Introduction QVA149 is a once-daily dual bronchodilator containing a fixed-dose combination of the long-  
indacaterol and the long-acting muscarinic antagonist glycopyrronium in development for the treatment of COPD  
symptom score results from three Phase III studies of QVA149. Methods All three studies were multicenter, double-blind  
which randomized patients (pts) ≥40 yrs with moderate-to-severe COPD. E-diaries were provided to pts to record  
Results The SHINE, ENLIGHTEN and ILLUMINATE studies randomized 2144, 523 and 339 pts, respectively. Q  
statistically significant improvements in symptom scores compared with other treatment groups as shown in table

Table: Mean treatment difference in symptom scores

	Least squares mean treatment difference (SE)				
	SHINE (26wks)				ENLIGHTEN (52wks)
	QVA149–placebo	QVA149–indacaterol	QVA149–glycopyrronium	QVA149–open-label tiotropium	QVA149–placebo
Nights with no nighttime awakenings, %	10.01 (2.368)***	1.20 (1.892)	5.05 (1.910)**	3.68 (1.891)	6.32 (3.610)
Days with no daytime symptoms, %	3.05 (1.485)*	–1.68 (1.180)	1.09 (1.191)	1.95 (1.180)	5.30 (2.100)
Days able to perform daily	11.48 (2.529)***	5.04 (2.014)*	5.87 (2.034)**	8.45 (2.014)***	8.13 (3.676)

activities, %					
Daily total symptom score	−0.67 (0.145)***	−0.13 (0.116)	−0.26 (0.117)*	−0.24 (0.116)*	−0.57 (0.22)

\*\*\*p<0.001, \*\*p<0.01, \*p<0.05

Conclusion Once-daily QVA149 provides improvements in COPD symptoms compared to indacaterol, glycopyrronium, or salmeterol/fluticasone.